ArticleScientific reports2026
Evaluating the clinical significance of tumor-expressed C-reactive protein in chromophobe renal cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-reactive Protein (CRP) has been established as a prognostic biomarker in various malignancies, with elevated serum levels correlating with poorer outcomes. However, the significance of tissue-based CRP expression specifically in chromophobe renal cell carcinoma (chRCC), remains inadequately characterized. This study investigates the potential prognostic relevance of intratumoral CRP expression from a substantial cohort of chRCC patients. We conducted a retrospective analysis of patients who underwent surgical intervention for chRCC. Comprehensive clinical data was collected, and immunohistochemical evaluation of tumor specimens was performed to assess intratumoral CRP expression patterns. The study included 81 chRCC patients, with intratumoral CRP expression identified in 35 cases (43.2%). Statistical analysis revealed no significant correlation between CRP expression status and clinical parameters. While 5-year overall survival (OS) analysis showed no statistically significant difference between CRP-positive versus CRP-negative tumors (86.4% versus 100.0%; p = 0.106), overall follow-up demonstrated a significantly higher mortality rate in patients with CRP-positive tumors compared to those with CRP-negative tumors (22.9% vs. 2.2%; p = 0.013). Our findings suggest that intratumoral CRP expression in chRCC is not clearly associated with parameters of aggressiveness or survival. Further studies should assess the possible correlation between CRP tissue expression and blood levels. However, these findings should be interpreted with caution given the limited sample size, low event rate, and high loss to follow-up, and are best considered hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.